Actively Recruiting
CHASE Registry of Patients With Pulmonary Hypertension Receiving Targeted Therapy
Led by Chinese Pulmonary Vascular Disease Research Group · Updated on 2024-01-18
5000
Participants Needed
1
Research Sites
417 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
CHina Registry for the chAracteristics and Management strategieS of patiEnts With Pulmonary Hypertension Using Targeted Therapy (CHASE Study)
CONDITIONS
Official Title
CHASE Registry of Patients With Pulmonary Hypertension Receiving Targeted Therapy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent
- Between the ages of 18 and 85
- Clinical diagnosis of pulmonary hypertension
- Currently using or planning to use targeted pulmonary hypertension drugs (including prostacyclin analogues, endothelin receptor antagonists, phosphodiesterase inhibitors, soluble guanylate cyclase agonists, prostacyclin receptor agonists)
You will not qualify if you...
- History of mental illness or drug/poison addiction preventing informed consent or cooperation
- Malignant tumor or other diseases with life expectancy under six months
- Taking targeted pulmonary hypertension drugs for less than 2 weeks
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Center for Respiratory and Pulmonary Vascular Diseases, Fuwai hospital, CAMS & PUMC
Beijing, China, 100037
Actively Recruiting
Research Team
Z
Zhihong Liu, M.D., Ph.D
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here